Premium
Risk of High‐Dose Erythromycin in End‐Stage Renal Disease
Author(s) -
Foote Edward F.
Publication year - 1994
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.1994.tb00823.x
Subject(s) - medicine , end stage renal disease , stage (stratigraphy) , erythromycin , disease , urology , intensive care medicine , antibiotics , microbiology and biotechnology , biology , paleontology
Is high‐dose (i.e., over 2 g daily) intravenous erythromycin contraindicated in end‐stage renal disease (ESRD) because of the risk of ototoxicity?